Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for 10 companies, including Gaoguang Pharmaceutical, which is preparing for a listing on the Hong Kong Stock Exchange [1] - Gaoguang Pharmaceutical is required to clarify its capital increase and share transfer pricing basis, compliance with capital contribution obligations, and legality of past equity changes [1] - The CSRC also requests details on shareholders holding over 5% of shares, including the legitimacy of new shareholder entry prices and potential conflicts of interest [1] Group 2 - Gaoguang Pharmaceutical's core products, TLL-018, TLL-041, and TLL-009, are unique selective TYK2/JAK1 inhibitors, with TLL-018 expected to be a leading treatment for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA) [2] - The company is conducting two Phase III registration trials for CSU and RA in China and plans to submit a New Drug Application (NDA) to the National Medical Products Administration by the end of 2026 [2] - TLL-041 is the first and only selective TYK2/JAK1 inhibitor with brain penetration capabilities, aimed at treating neurodegenerative diseases, and the collaboration with Biohaven represents a significant strategic partnership in this field [2]
高光制药拟港股上市 中国证监会要求补充说明股东情况等事项
Zhi Tong Cai Jing·2026-01-09 12:50